Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 450 of 494 entries
View as:

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

Phase: N/A Priority: Normal
NCT ID: NCT02443740 Org: User:
Start: 05/31/15 End: 10/31/15 Due: 10/31/16

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Phase: N/A Priority: Normal
NCT ID: NCT01864148 Org: User:
Start: 08/31/13 End: 03/31/16 Due: 03/31/17

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)

Phase: N/A Priority: Normal
NCT ID: NCT01780246 Org: User:
Start: 01/31/13 End: 02/28/14 Due: 02/28/15

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Phase: N/A Priority: Normal
NCT ID: NCT05229562 Org: User:
Start: 02/17/22 End: 09/07/22 Due: 09/07/23

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01462318 Org: User:
Start: 11/30/11 End: 01/31/16 Due: 01/31/17

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00536120 Org: User:
Start: 01/31/08 End: 12/31/09 Due: 12/31/10

PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants

Phase: N/A Priority: Normal
NCT ID: NCT02831517 Org: User:
Start: 08/31/16 End: 02/28/17 Due: 02/28/18

A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

Phase: N/A Priority: Normal
NCT ID: NCT05789758 Org: User:
Start: 12/15/23 End: 10/31/33 Due: 10/31/34

Natalizumab High Titer Immunogenicity and Safety

Phase: N/A Priority: Normal
NCT ID: NCT00516893 Org: User:
Start: 10/31/06 End: 12/31/07 Due: 12/31/08

Benepali® PEN Patient Satisfaction Survey

Phase: N/A Priority: Normal
NCT ID: NCT03327454 Org: User:
Start: 08/10/17 End: 06/21/18 Due: 06/21/19

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes

Phase: N/A Priority: Normal
NCT ID: NCT01930708 Org: User:
Start: 10/31/13 End: 01/09/20 Due: 01/09/21

Tecfidera Slow-Titration Study

Phase: N/A Priority: Normal
NCT ID: NCT02428231 Org: User:
Start: 04/30/15 End: 01/31/16 Due: 01/31/17

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04856982 Org: User:
Start: 05/17/21 End: 08/07/27 Due: 08/07/28

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03573505 Org: User:
Start: 09/24/18 End: 11/14/19 Due: 11/14/20

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Phase: N/A Priority: Normal
NCT ID: NCT00831649 Org: User:
Start: 09/30/04 End: - Due: -

AVONEX® Combination Trial - "ACT"

Phase: N/A Priority: Normal
NCT ID: NCT00112034 Org: User:
Start: 06/30/03 End: 05/31/07 Due: 05/31/08

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

Phase: N/A Priority: Normal
NCT ID: NCT03496012 Org: User:
Start: 12/11/17 End: 12/01/20 Due: 12/01/21

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Phase: N/A Priority: Normal
NCT ID: NCT05418673 Org: User:
Start: 08/26/22 End: 07/27/23 Due: 07/27/24

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

Phase: N/A Priority: Normal
NCT ID: NCT02159573 Org: User:
Start: 07/31/14 End: 01/31/15 Due: 01/31/16

Treatment Interruption of Natalizumab

Phase: N/A Priority: Normal
NCT ID: NCT01071083 Org: User:
Start: 03/31/10 End: 11/30/11 Due: 11/30/12

A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01500798 Org: User:
Start: 01/31/12 End: 10/01/13 Due: 10/01/14

A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders

Phase: N/A Priority: Normal
NCT ID: NCT05109637 Org: User:
Start: 02/10/22 End: 07/25/23 Due: 07/25/24

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT04442490 Org: User:
Start: 05/12/20 End: 04/21/21 Due: 04/21/22

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01058005 Org: User:
Start: 03/31/10 End: 04/30/12 Due: 04/30/13

A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT05399888 Org: User:
Start: 08/24/22 End: 01/08/29 Due: 01/08/30